Peak Sales Potential of Merck's (MRK) Keytruda is Underappreciated - Analyst

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. ENPH
2. HOOD
3. NXPI
4. SPY
5. BA
6. STX
7. NOW
8. GOOGL
9. GOOG
10. V

Go back to Peak Sales Potential of Merck's (MRK) Keytruda is Underappreciated - Analyst

U.S. FDA approves Merck's Keytruda combo for early breast cancer treatment

July 27, 2021 7:04 AM EDT

(Reuters) - Merck & Co Inc said on Tuesday that the U.S. Food and Drug Administration approved its immunotherapy Keytruda as a treatment for an early form of a tough-to-treat breast cancer in combination with chemotherapy.

The FDA approval is for treating triple-negative breast cancer (TNBC), an aggressive form of the disease with an increased risk of recurrence.... More

Merck (MRK) Announces Phase 3 KEYNOTE-355 Trial Met Primary Endpoint of Overall Survival (OS) in Patients with Metastatic Triple-Negative Breast Cancer Whose Tumors Expressed PD-L1

July 27, 2021 6:46 AM EDT

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive overall survival (OS) results from the pivotal Phase 3 KEYNOTE-355 trial evaluating KEYTRUDA, Mercks anti-PD-1 therapy, in combination with chemotherapy for the treatment of patients with metastatic triple-negative breast cancer (mTNBC). Findings from the final analysis show first-line treatment with KEYTRUDA in combination with chemotherapy (nab-paclitaxel, paclitaxel or gemcitabine/carboplatin) demonstrated a statistically significant and clinically meaningful improvement in OS compared with chemotherapy alone in patients with mTNBC whose tumors expressed PD-L1 (Combined Positive Score [CPS] 10). No new safety signals... More